SCHEDULE 13G/A: BlackRock Amends Nuvation Bio Stake, Reports 4.9% Beneficial Ownership

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Nuvation Bio Inc.'s Class A Stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Nuvation Bio Inc.'s Class A Stock.
• As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 16,440,206 shares of Nuvation Bio Inc. Class A Stock.
• This represents 4.9% of the Class A Stock outstanding.
• BlackRock, Inc. holds sole voting power over 16,081,247 shares and sole dispositive power over 16,440,206 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nuvation Bio Inc.
• BlackRock, Inc. is filing as a parent holding company and control person, with certain subsidiaries, including BlackRock Investment Management, LLC, contributing to the aggregate beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) reporting beneficial ownership. It does not contain positive or negative operational or financial news about the issuer, Nuvation Bio Inc., but rather a factual disclosure of an institutional investor's stake. The slight decrease in percentage (if it was previously above 5%) is not explicitly stated as negative, and the certification of ordinary course holding is neutral.

Positives

• The filing indicates a significant institutional investor, BlackRock, maintains a substantial stake in Nuvation Bio Inc., which can be viewed as a vote of confidence.
• BlackRock's certification that the shares are held in the ordinary course of business and not for control purposes suggests stability in the ownership structure.

Negatives

• The reported 4.9% beneficial ownership by BlackRock, Inc. is below the 5% threshold, which, as an amendment, could imply a reduction in their aggregate stake from a previously higher level, though the prior percentage is not disclosed.

Risks

• The document does not detail specific risks related to Nuvation Bio Inc.'s operations or financial health.
• The primary risk disclosed is the potential for misinterpretation of the filing, as the aggregate beneficial ownership reported by BlackRock, Inc. (4.9%) is for specific "Reporting Business Units" and does not include all securities beneficially owned by other BlackRock business units that are disaggregated.

Future Outlook

The document, a beneficial ownership report, does not provide any forward-looking statements or guidance regarding Nuvation Bio Inc.'s future performance or BlackRock's future investment intentions beyond the current reported stake.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This Schedule 13G filing is a routine disclosure required by the SEC when an institutional investor's beneficial ownership of a company's stock reaches or changes significantly from certain thresholds. It provides transparency into major institutional holdings, which can influence market perception and liquidity. BlackRock, as one of the world's largest asset managers, frequently files such reports across numerous public companies, reflecting its broad investment activities on behalf of its clients.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, which can influence market sentiment and liquidity. A potential decrease below 5% (if applicable) might be viewed differently than an increase.
• Employees, Customers, Suppliers, Creditors: Direct impact is minimal as this filing primarily concerns ownership structure, not operational changes.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Nuvation Bio Inc. or BlackRock, Inc. beyond the ongoing regulatory compliance.

Key Dates

Keywords

Nuvation Bio Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Class A Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Management